ICU Medical, Inc. reported a decline in revenue for the third quarter of 2025, generating $536.99 million compared to $589.13 million in the same period last year, marking a decrease of approximately 8.8%. For the nine months ending September 30, 2025, total revenues were $1.69 billion, down from $1.75 billion in 2024. The company experienced a net loss of $3.40 million for the quarter, a significant improvement from a loss of $32.98 million in the prior year. Year-to-date, ICU Medical reported a net income of $16.47 million, contrasting with a loss of $93.86 million for the same period in 2024.
The decrease in revenue was primarily attributed to the divestiture of a controlling interest in the IV Solutions business, which was completed on May 1, 2025. This strategic move allowed ICU Medical to focus on its core product lines, resulting in a gain of $44.79 million from the sale. The company also noted improvements in gross profit margins, which increased to 37.4% for the third quarter, up from 35% in the previous year, driven by price increases and operational efficiencies.
Operationally, ICU Medical's product lines showed varied performance. The Consumables segment saw revenue growth, attributed to new customer installations and increased demand, while the Infusion Systems segment also reported an increase in sales, particularly in large volume pump hardware. However, the Vital Care segment experienced a significant decline in revenue due to the sale of the IV Solutions business. The company’s total employee headcount remained stable, with no significant changes reported.
Looking ahead, ICU Medical is focused on integrating its recent acquisitions and managing the impacts of macroeconomic factors such as inflation and supply chain disruptions. The company has also entered into new credit facilities to refinance existing debt, which is expected to reduce interest expenses and improve liquidity. ICU Medical anticipates that these strategic decisions will position the company for future growth, despite the ongoing challenges in the healthcare market.
About ICU MEDICAL INC/DE
ICU Medical, Inc. develops, manufactures, and sells innovative medical products for infusion therapy, vascular access, and vital care. Its offerings include infusion pumps, IV sets, safety devices, and respiratory and anesthesia products. Serving hospitals, clinics, and healthcare providers worldwide, ICU emphasizes quality, safety, and regulatory compliance, leveraging a diversified product portfolio and global supply chain to deliver value and improve patient care.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.